About Us

Revive Therapeutics Ltd. (TSXv: RVV) (OTCQB: RVVTF) is focused on the research, development and commercialization of novel treatments for serious and unmet medical needs.  

Revive’s drug discovery approach combines bioinformatics and drug development relationships with leading researchers and institutions.

Revive targets opportunities by identifying and investigating potential drugs and plant-based therapies, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, or be developed as new chemical entities.

Revive has a multi-disciplinary scientific team of advisors who are experts in the discovery, development, delivery, manufacturing and marketing of drugs as well as in plant-based sciences.

Read more

news

News

January 24, 2017

Revive Therapeutics Appoints Dr. Pritesh Kumar as Scientific Advisor for Cannabinoid-Based Therapeutics

Read more
January 12, 2017

Revive Therapeutics Engages Massachusetts General Hospital for Cystinuria Phase 2 Study

Read more
December 21, 2016

Revive Therapeutics Engages NYU School of Medicine for Cystinuria Phase 2 Study

Read more
December 06, 2016

Revive Therapeutics Ltd. Announces Positive Study Results in Rett Syndrome

Read more
November 24, 2016

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2016

Read more
Newsletter